亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

武漢大華偉業醫藥化工公司  

醫藥中間體,原料藥,提取物

搜索
新聞中心
  • 暫無新聞
產品分類
  • 暫無分類
聯系方式
  • 聯系人:whdh123
  • 電話:027-59261278
  • QQ:572727836
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 供應氯雷他定原料藥廠家供應
供應氯雷他定原料藥廠家供應
單價 面議對比
詢價 暫無
發貨 湖北武漢市付款后3天內
品牌 武漢大華
過期 長期有效
更新 2012-10-23 14:32
 
詳細信息

5、采納25kg /紙板桶,內襯化合鋁膜袋。


相符中中藥典附錄規則重非金屬 ≤20ppm 相關精神 ≤1.0%
性狀白色結晶性粉末,無臭有趣。正在丙醇、酒精、鹽酸安非拉酮中易溶,乙醚中溶化。正在0.1mol/L鹽酸中微溶,正在0.1mol/L氫氧化鈉中沒有溶。熔點 133~137℃ 甄別 1、 本品與氯化汞試液生成白色積淀。 2、 本品的酒精濾液吸引跨度為:247nm。 3、 本品的HPLC峰的保存工夫應與比照品分歧 4、 本品的紅外線吸引圖譜與比照品的圖譜分歧。含量 98.5~101.0% 濾液的色彩與廓清度 1mg/ml酒精中廓清無色甲苯 ≤0.05% 正己烷 ≤0.029% 潮氣 ≤0.5% 灼燒殘渣 ≤0.2%

貨物英文稱號:Loratadine
品質規范:USP31
 

貨物稱號:氯雷他定


包裝:25公斤/桶



含量:99.8(%) 


規格:醫藥級


CAS號:79794-75-5
成員量:382.89

成員式:C22H23ClN2O2


貨物稱號:氯雷他定


©2025 武漢大華偉業醫藥化工公司 版權所有   技術支持:化工網   訪問量:15636  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |